Consensus or Controversy

Consensus or Controversy, Issue 4: New Agents and Strategies in the Management of Breast Cancer — Part 4, Checkpoint Inhibitors in Triple-Negative Disease
Clinical investigators provide concise comments on the use of checkpoint inhibitors in the treatment of triple-negative disease. Featuring perspectives from Drs Carey K Anders, Aditya Bardia, Erika Hamilton, Sara Hurvitz, Virginia Kaklamani, Ruth O’Regan, Joyce O’Shaughnessy, Mark D Pegram and Sara M Tolaney.
Consensus or Controversy, Issue 3: New Agents and Strategies in the Management of Breast Cancer — Part 3, Practical Integration of PARP Inhibitors
Clinical investigators provide concise comments on the integration of PARP inhibitors into breast cancer management. Featuring perspectives from Drs Carey K Anders, Aditya Bardia, Erika Hamilton, Sara Hurvitz, Virginia Kaklamani, Ruth O’Regan, Joyce O’Shaughnessy, Mark D Pegram and Sara M Tolaney.
Consensus or Controversy, Issue 2: New Agents and Strategies in the Management of Breast Cancer — Part 2, ER-Positive Metastatic Disease
Clinical investigators provide concise comments on the treatment of ER-positive metastatic breast cancer. Featuring perspectives from Drs Carey K Anders, Aditya Bardia, Erika Hamilton, Sara Hurvitz, Virginia Kaklamani, Ruth O’Regan, Joyce O’Shaughnessy, Mark D Pegram and Sara M Tolaney.
Consensus or Controversy, Issue 1: New Agents and Strategies in the Management of Breast Cancer — Part 1, Localized HER2-Positive Disease
Clinical investigators provide concise comments on the treatment of localized HER2-positive breast cancer. Featuring perspectives from Drs Carey K Anders, Aditya Bardia, Erika Hamilton, Sara Hurvitz, Virginia Kaklamani, Ruth O’Regan, Joyce O’Shaughnessy, Mark D Pegram and Sara M Tolaney.

Browse byTumor Type

Consensus or Controversy

Consensus or Controversy, Issue 4: New Agents and Strategies in the Management of Breast Cancer — Part 4, Checkpoint Inhibitors in Triple-Negative Disease

Consensus or Controversy, Issue 3: New Agents and Strategies in the Management of Breast Cancer — Part 3, Practical Integration of PARP Inhibitors

Consensus or Controversy, Issue 2: New Agents and Strategies in the Management of Breast Cancer — Part 2, ER-Positive Metastatic Disease

Consensus or Controversy, Issue 1: New Agents and Strategies in the Management of Breast Cancer — Part 1, Localized HER2-Positive Disease

Browse by
Tumor Type